Incyte Corporation
NASDAQ:INCYBiotechnology
-$0.77 today
- Market cap
- $24.01B
- Beta
- 0.79
- P/E (TTM)
- 13.7
- EPS (TTM)
- $7.18
Volume 1.21M
Average 1.58M
INCY Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Incyte CorporationNASDAQ: INCY
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin holds steady near 93.7%
Gross margin was 93.7% in Q2 FY2026, up 0.2 pp from a year earlier. On a trailing-twelve-month basis it was 92.6%, down 0.3 pp year over year. Over 3 fiscal years it narrowed by 1.1 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 92.8%
- Year-over-year change
- +0.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 92.8% | +0.1pp |
| FY2024 | 2024-12-31 | 92.6% | -0.5pp |
| FY2023 | 2023-12-31 | 93.1% | -0.8pp |
| FY2022 | 2022-12-31 | 93.9% | -1.0pp |
| FY2021 | 2021-12-31 | 94.9% | — |
Gross Margin vs competitors
How INCY compares with its peers on the latest reported figures
- INCY's LTM Jun 2026 gross margin of 92.6% is the 4th highest of the 8 companies compared; the peer median is 86.5%.
- Its year-over-year change of -0.3 pp is the 4th highest of 7, against a peer median of -0.4 pp.
- Over three fiscal years its change of -1.1 pp compares with a peer median of -0.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 98.6% | +10.9 pp | +24.5 pp | |
| LTM Jul 2026 | 96.5% | -0.1 pp | -0.0 pp | |
| LTM Jun 2026 | 93.0% | — | -8.3 pp | |
| LTM Jun 2026 | 92.6% | -0.3 pp | -1.1 pp | |
| LTM Aug 2026 | 86.5% | +249.4 pp | +455.2 pp | |
| LTM Jun 2026 | 84.9% | -0.7 pp | -0.6 pp | |
| LTM Mar 2026 | 83.7% | -16.3 pp | -17.1 pp | |
| LTM Sep 2026 | 57.0% | -3.6 pp | +16.2 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding INCY) | 86.5% | -0.4 pp | -0.0 pp | |
Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.99B | 3.39B | 3.7B | 4.24B | 5.14B |
| Cost of Revenue | 150.99M | 207M | 254.99M | 312.1M | 372.1M |
| Gross Profit | 2.84B | 3.19B | 3.44B | 3.93B | 4.77B |
| Gross Margin | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% |
| Research & Development | 1.46B | 1.59B | 1.63B | 2.61B | 2.05B |
| Selling, General & Admin | 739.56M | 1B | 1.16B | 1.22B | 1.38B |
| Operating Expenses | 2.25B | 2.6B | 2.79B | 3.83B | 3.43B |
| Depreciation & Amortization | 57.84M | 67.86M | 82.66M | 89.25M | 93.29M |
| EBITDA | 630.2M | 599.64M | 919.43M | 408.16M | 1.76B |
| EBITDA Margin | 21.1% | 17.7% | 24.9% | 9.6% | 34.2% |
| Operating Income | 585.78M | 591.63M | 655.36M | 101.29M | 1.34B |
| Operating Margin | 19.6% | 17.4% | 17.7% | 2.4% | 26.1% |
| Interest Income | 0 | 0 | 0 | 128.71M | 105.6M |
| Interest Expense | 1.91M | 2.67M | 2.55M | 2.28M | 2.43M |
| Other Income / Expenses | (15.33M) | (62.51M) | 178.86M | 215.34M | 321.66M |
| Income Before Tax | 570.44M | 529.12M | 834.22M | 316.63M | 1.66B |
| Pre-Tax Margin | 19.1% | 15.6% | 22.6% | 7.5% | 32.4% |
| Income Tax Expense | (378.14M) | 188.46M | 236.62M | 284.02M | 377.8M |
| Net Income | 948.58M | 340.66M | 597.6M | 32.62M | 1.29B |
| Net Margin | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% |
| EPS (Basic) | 4.30 | 1.53 | 2.67 | 0.16 | 6.59 |
| EPS (Diluted) | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 |
| Weighted Avg Shares | 220.43M | 222M | 223.63M | 207.11M | 195.2M |
| Weighted Avg Shares (Diluted) | 222.07M | 223.96M | 225.93M | 210.53M | 200.7M |
Incyte Corporation
NASDAQ:INCY
Intrinsic Alpha fair value
Locked
Current Price
$117.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.